The immunological aspects of conventional therapies for the treatment of cervical cancer. An exploratory study to monitor the immunological effects of radiotherapies in cervical cancer patients

Completed

• Conditions: cancer of the cervix; cervical cancer; 10038594

• Registration Number: NL-OMON35864
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

- Patients should be at least 18 years of age;
- Patients should be able and willing to provide informed consent;
- Patients should have the clinical diagnosis of cervical cancer;
- Patients are scheduled for:
1. Primary external beam radiotherapy (EBRT) with intra-uterine brachytherapy (BT);
2. Primary EBRT with intra-uterine brachytherapy (BT) and concurrent chemotherapy (Cisplatin);
3. Primary EBRT with intra-uterine brachytherapy (BT) and combined with hyperthermia;
4. Adjuvant, post-operative external beam radiotherapy (EBRT);
5. Adjuvant, post-operative EBRT with concurrent chemotherapy (Cisplatin).

Exclusion Criteria

- Any medical condition that may interfere with the study objectives;
- Positive test result for HIV or Hepatitis B;
- Any other active malignancy than cervical cancer.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The time-related immuneresponse during and after treatment with radiotherapy in<br /><br>cervical cancer patients. T cell phenotypic changes and T cell-related immune<br /><br>cell functional changes will be investigated.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>